目的 探讨 Her⁃2 阳性乳腺癌新辅助化疗联合靶向治疗获得病理完全缓解（pCR）的影响因素。方法 回顾性分析 185 例初次确诊并接受新辅助化疗联合靶向治疗的 Her⁃2 阳性乳腺癌患者的临 床病理资料，分析获得 pCR 的相关因素。结果 患者总体 pCR 率为 53.5%。雌孕激素受体状态、Her⁃2 阳性确诊方式、靶向治疗方案是影响 pCR 率的独立相关因素（P < 0.05）。激素受体阴性比阳性更容易获得 pCR（OR = 4.829，95%CI：2.399 ~ 9.721，P < 0.001），Her⁃2 免疫组化 2+且 FISH 阳性较 Her⁃2 免疫组化 3+ 更不容易获得 pCR（OR = 0.430，95%CI：0.191 ~ 0.971，P = 0.042），双靶治疗比单靶更容易获得 pCR（OR = 2.203，95%CI：1.147 ~ 4.232，P = 0.018）。结论 激素受体阴性、Her⁃2 免疫组化 3+、接受双靶治疗的 Her⁃2 阳性乳腺癌患者更容易在新辅助化疗加靶向治疗中获得pCR。

Objective To explore the influencing factors of pathological complete response（pCR）by neoadjuvant chemotherapy（NAC）combined with targeted therapy for Her⁃2 positive breast cancer. Methods The clinical and pathological data of 185 patients with HER⁃2 positive breast cancer who were initially diagnosed and received NAC combined with targeted therapy were retrospectively analyzed. Univariate and multivariate analysis were used to find the factors associated with pCR. Results The overall pCR rate was 53.5%. Estrogen and proges⁃ terone receptor status，HER ⁃2 positive mode of diagnosis，and targeted therapy regimen were independent factors associated with pCR rate（P < 0.05）. Patients with hormone receptors negative were more likely to achieve pCR than positive（OR = 4.829，95%CI：2.399 ~ 9.721，P < 0.001），patients with HER⁃2 2+ and FISH positive were less likely to achieve pCR than HER⁃2 3+（OR = 0.430，95%CI：0.191 ~ 0.971，P = 0.042），and patients with dual ⁃target therapy were more likely to achieve pCR than single ⁃target therapy（OR = 2.203，95%CI：1.147 ~ 4.232，P = 0.018）. Conclusions Her⁃2 positive breast cancer patients with hormone receptor negative，Her⁃2 3+ or double target therapy are more likely to obtain pCR in NAC combined with targeted therapy.